• In late May and early June 2026, Agilent Technologies reported higher quarterly sales and earnings, raised its fiscal 2026 revenue guidance to US$7.39–US$7.49 billion, expanded FDA-approved use of its PD-L1 IHC 22C3 pharmDx diagnostic, launched several new lab software and instrument products, and announced an enterprise-wide AI collaboration with OpenAI and Boston Consulting Group.
• Together, these moves highlight Agilent’s push to deepen its role in regulated lab workflows, broaden oncology diagnostics on its platforms, and embed artificial intelligence across instruments, software, and services.
• We’ll now examine how Agilent’s new OpenAI collaboration could reshape its investment narrative around AI-enabled lab automation and services.

Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

Agilent Technologies Investment Narrative Recap

To own Agilent, you need to believe in its role as a core provider of lab instruments, software, and diagnostics across regulated end markets. The key shorter term catalyst is execution on higher 2026 revenue guidance, while the biggest current risk remains margin pressure from tariffs and supply chain complexity. The latest product and AI announcements support the growth narrative but do not materially change these near term swing factors.

The new enterprise AI collaboration with OpenAI and Boston Consulting Group looks most relevant right now, because it directly targets product development speed, instrument intelligence, and customer workflows. For investors focused on catalysts, this sits alongside recent software launches like OpenLab Sync and QC oriented workflows as part of a broader push toward higher value, stickier lab informatics and services.

Yet behind the upbeat guidance and AI push, investors should be aware of rising tariff related cost risk if mitigation efforts prove slower or less effective than...

Agilent Technologies' narrative projects $8.8 billion revenue and $2.1 billion earnings by 2029. This requires 6.7% yearly revenue growth and roughly a $0.7 billion earnings increase from $1.4 billion today.

Uncover how Agilent Technologies' forecasts yield a $161.00 fair value, a 19% upside to its current price.

Exploring Other Perspectives

Four members of the Simply Wall St Community currently estimate Agilent’s fair value between US$150.54 and US$170.92, underscoring how far opinions can differ. When you set those views against tariff driven cost risks and the company’s dependence on capital replacement cycles, it is worth exploring multiple scenarios for how Agilent can perform over time.

Explore 4 other fair value estimates on Agilent Technologies - why the stock might be worth as much as 26% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Agilent Technologies research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Agilent Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Agilent Technologies' overall financial health at a glance.

Contemplating Other Strategies?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• AI is about to change healthcare. These 38 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Explore 30 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.